Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) | --- | --- | --- | --- | |----------------------------------------------------|-------|-----------------------------|--------------------------| | Assets | Note | As \nSeptember 30, 2024 | of \nDecember 31, 2023 | | Non-current assets | | | | | Property, plant and equipment | 5 | 2,736 | 3,376 | | Right-of-use assets | 6 | 3,091 | 3,508 | | Intangible asset | 8 | 50,416 | 50,416 | | Long-term financial assets | 6 | 415 | 361 ...

AC Immune (ACIU) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of $0.42. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -159.52%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.15 per share when it actually produced a loss of $0.21, delivering a surprise of -40%.Over the last four quarters, the company has surpas ...

AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Announced exclusive option and license agreement with Takeda for ACI-24.060 on May 13 for $100 million upfront and total potential milestones of up to approximately $2.1 billionACI-24.060 ABATE Phase 2 trial in Alzheimer's disease (AD) on track with enrolment expectationsACI-7104.056 VacSYn Phase 2 trial of anti-a-syn active immunotherapy in Parkinson's disease (PD) on track for safety and immunogenicity interim data in ...

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 morADC combines proprietary brain-penetrant small molecule Morphomers® with SupraAntigen® monoclonal antibodies, forming a new class of drug-candidates to target toxic proteins in CNS morADC demonstrated significant synergies, substantially increasing blood brain barrier penetration and potency to inhibit protein aggregation compared to the antibody or small molecule ...

FG Trade/E+ via Getty Images The last time I wrote about AC Immune SA (NASDAQ:ACIU), it was in a Seeking Alpha article entitled "AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts." In this article, I wrote about the prospects of its anti-Abeta active immunotherapy ACI-24.060 immunotherapy candidate being used to treat patients with Alzheimer's Disease [AD]. The use of this vaccine immunotherapy is currently being explored in the ongoing phase 2 ABATE trial. This trial is split up into target ...

AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer's Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060, and ACI-19626 Lausanne, Switzerland, July 16, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced three oral presentations highligh ...

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 Global Healthcare Conference, taking place in-person ...

AC Immune (NASDAQ:ACIU) stock is heading higher on Monday alongside the clinical-stage biopharmaceutical company's earnings report for the first quarter of 2024. Included in that earnings report is an operational update that covers a new collaboration agreement with Takeda Pharmaceutical (NYSE:TAK). This has Takeda Pharmaceutical signing a licensing agreement for AC Immune's ACI-24.060. This agreement includes an upfront payment of $100 million to AC Immune. It also covers potential payments of up to $2.1 b ...

Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of March 31, December 31, Note 2024 2023 Assets Non-current assets Property, plant and equipment 5 3,236 3,376 Right-of-use assets 6 3,341 3,508 Intangible asset 8 50,416 50,416 Long-term financial assets 6 415 361 Total non-current assets 57,408 57,661 Current assets Prepaid expenses 9 3,917 6,437 Accrued income 3 267 246 Other current receivables 868 622 Accounts receivable 11 — 14,800 Short-term financial assets 10 47,81 ...

AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for option exercise and milestones of up to approximately $2.1 billionACI-24.060 ABATE Phase 2 trial on track to report Abeta-PET imaging results in Q2 2024, evaluating amyloid plaque reduction after 6 months of anti-Abeta active immunotherapyACI-7104.056 VacSYn Phase 2 trial of anti-a-syn active immunotherapy in Park ...